CSPG4 and head and neck squamous cell carcinoma: To date, only one CSPG4-targeted CAR T cell construct has progressed to phase 1/2 clinical trial (ClinicalTrials.gov, NCT06096038) for patients with head and neck squamous cell carcinoma (HNSCC).